Drugs / gemtuzumab ozogamycin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00860639 Comparator | Oct 2007 → Sep 2016 | acute myeloid leukemia | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gemtuzumab ozogamycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00860639 ↗ |
| Known as | gemtuzumab ozogamycin (MYLOTARG ) | “gemtuzumab ozogamycin (MYLOTARG ®)” NCT00860639 ↗ |
| Route | Intravenous | “administered according to the randomization arm on the 4th day of treatment by slow intravenous infusion of 2 hours” NCT00860639 ↗ |